search
Back to results

Comparative Study for the Evaluation of a New Medical Device on the Treatment of Head Lice Infestation

Primary Purpose

Head Lice

Status
Recruiting
Phase
Not Applicable
Locations
Mauritius
Study Type
Interventional
Intervention
INVESTIGATIONAL DEVICE
Comparator device
Sponsored by
Perrigo CSCI
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Head Lice

Eligibility Criteria

2 Years - undefined (Child, Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Healthy subject;
  2. Sex: male or female;
  3. Age: 2 years and above;
  4. Subject with a slight to moderate lice infestation
  5. Subjects with various hair type (from 1 to 3C - hair scale) and hair length (from short to mid length hair, not exceeding shoulder)
  6. Documented oral informed consent for all subjects, including minors, given freely and expressly before the start of the study
  7. Written informed consent for subjects ≥18 years or legal guardian for subjects< 18 years given freely and expressly before start of the study;
  8. Written assent for subjects ≥12 to <18 years.
  9. Subject/Subject's legal guardian is psychologically able to understand the study related information and to give written informed consent;
  10. Females of childbearing potential must have a negative pregnancy test before the beginning of the study

Exclusion Criteria:

In terms of population

  1. Pregnant (confirmed by pregnancy test for women of childbearing potential) or nursing woman or planning a pregnancy during the study;
  2. Subject who had been deprived of their freedom by administrative or legal decision or adult subject who is under guardianship;
  3. Subject in a social or sanitary establishment;
  4. Subject in an exclusion period from a previous study or who is currently participating to another study on hair/scalp or who participated to another clinical study on hair/scalp within 3 months before first visit.
  5. Subject suspected to be non-compliant according to the Investigator's judgment.
  6. Subject with curly or frizzy hair (type 4a to 4c in the hair type scale above)
  7. Subject with hair length below the shoulder.
  8. Subjects with more than 24 lice on the head

    In terms of associated pathology

  9. Subject suffering from a severe or progressive disease or any other pathology that may interfere with the evaluation of the study results.
  10. Subject with a cutaneous disease on the studied zone (scalp and hair).
  11. Subject with severe scratches or open wounds/skin damages on the scalp (lice bites allowed however).
  12. Subject with a known or suspected allergy to any of the components/materials of the investigational or comparator devices, anti-lice comb or post-treatment shampoo.
  13. Subject who has diabetes (type 1 or 2).
  14. Subject with known or suspected immune deficiency or autoimmune disease.

    Relating to previous or ongoing treatment

  15. Subject undergoing a topical treatment on the test area or a systemic treatment with :

    • anti-inflammatory medication and/or anti-histamines during the previous 2 weeks and during the study;
    • corticosteroids during the 2 previous weeks and during the study;
    • retinoids and/or immunosuppressors during the 3 previous months and during the study;
    • any medication stabilized for less than one month.
  16. Subject who received an anti-lice treatment in the previous 2 months.

Sites / Locations

  • Céline LhéritierRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

INVESTIGATIONAL DEVICE

COMPARATOR DEVICE

Arm Description

new medical device for the treatment of head lice infestation: Paranix ®

dimethicone based head lice treatment (medical device class 1) already in market in europe: Pouxit ®

Outcomes

Primary Outcome Measures

Cure Rate after complete treatment
The cure rate is defined as the rate of subjects having no live lice on scalp 7 days after the last application of the product.
Cure Rate after complete treatment
The cure rate is defined as the rate of subjects having no live lice on scalp 7 days after the last application of the product.

Secondary Outcome Measures

Cure rate after one dose of Investigational device (ID)
Comparison of the percentage of subjects cured after one dose of the investigational device compared to the percentage of subjects cured with two doses of the comparator device.
Dead and live lice/nymphs and number of eggs after combing
Number of dead and live lice/nymphs and number of eggs collected on the anti-lice comb after treatment
Live lice and nymphs, after application
Evaluation of the presence of live lice and nymphs, for both groups, without combing on scalp
Number of participants with treatment-related adverse events as assessed by investigator
Evaluation of the safety and tolerability of the investigational device versus comparator
Subject reported perceived acceptability, effectiveness and subjective evaluation assessed via questionnaire data
Evaluation of the perceived acceptability, effectiveness and subjective evaluation. Subject perception questionnaire with the following scale items: totally agree agree rather agree rather disagree disagree

Full Information

First Posted
May 6, 2022
Last Updated
May 31, 2022
Sponsor
Perrigo CSCI
search

1. Study Identification

Unique Protocol Identification Number
NCT05379114
Brief Title
Comparative Study for the Evaluation of a New Medical Device on the Treatment of Head Lice Infestation
Official Title
Comparative, Monocentric Study for the Evaluation of the Non-inferiority of a New Medical Device on the Treatment of Head Lice Infestation
Study Type
Interventional

2. Study Status

Record Verification Date
May 2022
Overall Recruitment Status
Recruiting
Study Start Date
May 18, 2022 (Actual)
Primary Completion Date
July 2022 (Anticipated)
Study Completion Date
September 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Perrigo CSCI

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Pediculosis capitis or head lice infestation is a human medical condition caused by the infestation of the hair by the parasitic insect Pediculus humanus capitis (human head lice). The most common symptom of infestation is pruritus (itching) on the head which normally intensifies 3 to 4 weeks after the initial infestation. The test item has been developed with the ambition to offer a complete head lice treatment, whilst also offering ultimate convenience in use - making treatment of head lice infestation easy, and effective in few minutes. The objectives of this clinical study are to assess the efficacy and the safety of a new Medical Device for lice infestation treatment compared to a comparator device, already in market.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Head Lice

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
136 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
INVESTIGATIONAL DEVICE
Arm Type
Experimental
Arm Description
new medical device for the treatment of head lice infestation: Paranix ®
Arm Title
COMPARATOR DEVICE
Arm Type
Active Comparator
Arm Description
dimethicone based head lice treatment (medical device class 1) already in market in europe: Pouxit ®
Intervention Type
Other
Intervention Name(s)
INVESTIGATIONAL DEVICE
Intervention Description
new medical device for the treatment of head lice infestation: Paranix ®
Intervention Type
Other
Intervention Name(s)
Comparator device
Intervention Description
well established medical device for the treatment of head lice infestation (dimethicone based) - Pouxit ®
Primary Outcome Measure Information:
Title
Cure Rate after complete treatment
Description
The cure rate is defined as the rate of subjects having no live lice on scalp 7 days after the last application of the product.
Time Frame
day 7
Title
Cure Rate after complete treatment
Description
The cure rate is defined as the rate of subjects having no live lice on scalp 7 days after the last application of the product.
Time Frame
day 14
Secondary Outcome Measure Information:
Title
Cure rate after one dose of Investigational device (ID)
Description
Comparison of the percentage of subjects cured after one dose of the investigational device compared to the percentage of subjects cured with two doses of the comparator device.
Time Frame
Day 7
Title
Dead and live lice/nymphs and number of eggs after combing
Description
Number of dead and live lice/nymphs and number of eggs collected on the anti-lice comb after treatment
Time Frame
Day 0 and Day 7 if applicable
Title
Live lice and nymphs, after application
Description
Evaluation of the presence of live lice and nymphs, for both groups, without combing on scalp
Time Frame
Day 1 and Day 8 if applicable
Title
Number of participants with treatment-related adverse events as assessed by investigator
Description
Evaluation of the safety and tolerability of the investigational device versus comparator
Time Frame
Day 0, 7, 8 and 14 if applicable
Title
Subject reported perceived acceptability, effectiveness and subjective evaluation assessed via questionnaire data
Description
Evaluation of the perceived acceptability, effectiveness and subjective evaluation. Subject perception questionnaire with the following scale items: totally agree agree rather agree rather disagree disagree
Time Frame
Day 7 or Day14

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy subject; Sex: male or female; Age: 2 years and above; Subject with a slight to moderate lice infestation Subjects with various hair type (from 1 to 3C - hair scale) and hair length (from short to mid length hair, not exceeding shoulder) Documented oral informed consent for all subjects, including minors, given freely and expressly before the start of the study Written informed consent for subjects ≥18 years or legal guardian for subjects< 18 years given freely and expressly before start of the study; Written assent for subjects ≥12 to <18 years. Subject/Subject's legal guardian is psychologically able to understand the study related information and to give written informed consent; Females of childbearing potential must have a negative pregnancy test before the beginning of the study Exclusion Criteria: In terms of population Pregnant (confirmed by pregnancy test for women of childbearing potential) or nursing woman or planning a pregnancy during the study; Subject who had been deprived of their freedom by administrative or legal decision or adult subject who is under guardianship; Subject in a social or sanitary establishment; Subject in an exclusion period from a previous study or who is currently participating to another study on hair/scalp or who participated to another clinical study on hair/scalp within 3 months before first visit. Subject suspected to be non-compliant according to the Investigator's judgment. Subject with curly or frizzy hair (type 4a to 4c in the hair type scale above) Subject with hair length below the shoulder. Subjects with more than 24 lice on the head In terms of associated pathology Subject suffering from a severe or progressive disease or any other pathology that may interfere with the evaluation of the study results. Subject with a cutaneous disease on the studied zone (scalp and hair). Subject with severe scratches or open wounds/skin damages on the scalp (lice bites allowed however). Subject with a known or suspected allergy to any of the components/materials of the investigational or comparator devices, anti-lice comb or post-treatment shampoo. Subject who has diabetes (type 1 or 2). Subject with known or suspected immune deficiency or autoimmune disease. Relating to previous or ongoing treatment Subject undergoing a topical treatment on the test area or a systemic treatment with : anti-inflammatory medication and/or anti-histamines during the previous 2 weeks and during the study; corticosteroids during the 2 previous weeks and during the study; retinoids and/or immunosuppressors during the 3 previous months and during the study; any medication stabilized for less than one month. Subject who received an anti-lice treatment in the previous 2 months.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Céline Lhéritier
Phone
+33 (0)6 71 32 33 20
Email
clh@dermscan.com
Facility Information:
Facility Name
Céline Lhéritier
City
Quatre Bornes
Country
Mauritius
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Céline Lhéritier
Phone
+33671323320
Email
clh@dermscan.com
First Name & Middle Initial & Last Name & Degree
Aslham DOARIKA, Dr

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Comparative Study for the Evaluation of a New Medical Device on the Treatment of Head Lice Infestation

We'll reach out to this number within 24 hrs